A Clinical Stage Kidney CompanyTargeting Integrins with Allosteric Activators as Therapeutics Learn More
What We Do
149 Bio is a private company developing breakthrough medicines against integrin receptors to treat kidney and other diseases with high unmet need. We are using our proprietary CellStaple platform to identify and develop novel therapeutics.
Our founders were among the first to identify and develop a new modality to target integrins and take it to clinic – allosteric agonists of integrins as a highly differentiated and novel therapeutic modality. We are using this mechanism to develop therapeutics against many different integrin targets.
At 149 Bio, our Mission is to discover and develop breakthrough medicines for diseeases with high unmet need.
Our shared vision is a world where patients enjoy high quality of life with the help of targeted therapies to treat their underlying disease.
149 Bio is a startup company developing breakthrough medicines that target integrin receptors to treat diseases with high unmet need.
As an example of the unmet need in kidney disease:
- ~15% of general population suffers from Chronic Kidney Disease (CKD) during their life time.
- Diabetes and High Blood Pressure are leading causes of CKD.
- Diabetic Nephropathy (DN) is growing globally.
- Genetic changes result in CKD, such as Alport Syndrome, Focal Segmental Glomerulosclerosis (FSGS).
- More than 660,000 Americans suffer from Kidney failure.
- >90,000 patients/yr die due to Kidney Disease.
- Better treatment options are urgently needed.
- New therapeutics has been lacking due to shortage of good screening methods.
- At 149 Bio, we have developed a novel proprietary platform, that we call CellStaple, to identify and develop novel therapeutic candidates.
- Our platform allows rapid discovery of novel agents, as well as determine their mechanism of action to allow rapid drug development.
Team 149 Bio is highly experienced in drug discovery and development.
Our expertise is in targeting integrins in multiple therapeutic areas, including kidney disease.
Vineet Gupta is the Founder and CEO of 149 Bio. Vineet is an expert in the field of integrins and was among the first to identify allosteric agonists as a differentiated therapeutic modality to target integrins and demonstrated the therapeutic efficacy of this modality in human patients.
Vineet is a successful entrepreneur and has taken two startups from concept to exit, where he was the founder CEO. Most recently, his startup Adhaere Pharmaceuticals, Inc was acquired by Gossamer Bio, Inc. Vineet has extensive expertise in the field of integrins, high-throughput drug discovery and therapeutic development, and has been successful in taking compounds from discovery into the clinic. Vineet’s research is focused in the areas or auto-immune disease, kidney disease, cardiovascular diseases and oncology. He is widely published in high-impact peer-reviewed literature and has >50 patents/applications to his credit.
Vineet received his Master’s of Science in Chemistry from the Indian Institute of Technology, Delhi (IIT Delhi) and his PhD in Chemistry from University of Rochester. He did his post-doctoral studies at The Rockefeller University and at Harvard Medical School. He previously held faculty positions at the Massachusetts General Hospital/Harvard Medical School and at University of Miami. He has also previously worked at various biotech companies. He is also an Endowed Professor and Vice Chair for Innovation in the Department of Internal Medicine at Rush University Medical Center, Chicago, IL and holds The Charles Arthur Weaver Chair for Cancer Research.
Tony Barbosa is the Vice President of Research at 149 Bio. Tony is an accomplished Medicinal Chemist, with expertise in small molecule drug discovery and development. He has designed/developed compounds against a number of highly validated targets, including several integrins, and has been successful in taking compounds from discovery into the clinic.
Tony received his Bachelor’s in Science from Providence College and his PhD in Organic Chemistry from the University of Rochester. Previously, he was Director of Chemistry at Adhaere Pharmaceuticals, Inc (acquired by Gossamer Bio, Inc). Tony is currently also the Chair of the Department of Chemistry & Physics at Ave Maria University. He has also worked at multiple pharmaceutical and biotech companies in the past.
Kidneys are the essential organs in our body that filter waste from blood. Each of our two kidneys contain a million tiny cellular sieves, called nephrons, that filter urine away from blood. Being part of our cardiovascular system, other systemic changes, such as diabetes, hypertension, high fat diet and obesity, negatively impacts the normal function of the kidney. Additionally, certain genetic mutations or environmental stressors pose a threat to the kidney and reduce kidney function. Collective knowledge in the kidney field has identified a number of cellular and molecular pathways and targets that can now be effectively targeted with novel therapeutics.
Target Disease Areas
GI diseases (such as IBD)
Kidney Disease By the Numbers
# of Nephrons per Human Kidney
Patients with Kidney Failure
General Population suffers from Kidney Disease
Number of Approved New Medicines
Our Platform Technologies
We are utilizing our unique and proprietary Drug Discovery Platform to identify and advance novel candidate therapeutics.
149 Bio is growing. Please see the link below for current openings.
149 Bio, LLC
1951 NW 7th Avenue, Suite 600 Miami, FL 33136
© 2023 149 Bio LLC. All rights reserved.